Infant Financial Statements From 2010 to 2024
| IBT-B Stock | SEK 39.40 0.60 1.55% |
Check Infant Bacterial financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Infant Bacterial's main balance sheet or income statement drivers, such as , as well as many indicators such as . Infant financial statements analysis is a perfect complement when working with Infant Bacterial Valuation or Volatility modules.
Infant |
Infant Bacterial Therapeutics Company Current Valuation Analysis
Infant Bacterial's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Infant Bacterial Current Valuation | 271.56 M |
Most of Infant Bacterial's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infant Bacterial Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Infant Bacterial Therapeutics has a Current Valuation of 271.56 M. This is 98.11% lower than that of the Healthcare sector and 94.15% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 98.37% higher than that of the company.
Infant Bacterial Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Infant Bacterial's current stock value. Our valuation model uses many indicators to compare Infant Bacterial value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Infant Bacterial competition to find correlations between indicators driving Infant Bacterial's intrinsic value. More Info.Infant Bacterial Therapeutics is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Infant Bacterial's earnings, one of the primary drivers of an investment's value.About Infant Bacterial Financial Statements
Infant Bacterial shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Infant Bacterial investors may analyze each financial statement separately, they are all interrelated. The changes in Infant Bacterial's assets and liabilities, for example, are also reflected in the revenues and expenses on on Infant Bacterial's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Infant Bacterial Therapeutics AB , a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company was founded in 2013 and is based in Stockholm, Sweden. Infant Bacterial is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.